Life Sciences
We advise biotech, pharma, and CDMO companies on the transactions that define their trajectory — combining sector depth with a global partner network.
M&A Advisory
Sell-side and buy-side M&A for life sciences companies — from emerging biotech to established pharma. We manage the full process with discretion and rigour.
Licensing In & Out
Helping biotech and pharma assets find global licensing partners. We bridge science, strategy, and dealcraft to maximise value.
Business Development
For life sciences companies seeking to expand their commercial footprint. We identify, structure, and negotiate BD relationships that create long-term value.
Deal Flow Process
Four pillars behind every mandate.
Small & Mid-Cap Focus
- Specializing in small and medium size transactions (USD $50–150 million).
- Understand champions of innovation and business models of outstanding private companies.
Global Business Networks
- Long-standing partnership with EMEA family business associations.
- Co-operation with OECD, European Commission, Governments, Chambers of Commerce, and Entrepreneurs Associations.
Extensive on-the-ground network with big Pharma CDMOs and clinical-stage biotech across China and Europe.
Human Centric Communication
- Flexible and customized approach to assist clients walk through the deal cycle.
Independent and Ready to Go
- Cross-functional team with rich, relevant transaction experience.
Selected Transactions
Advised a listed Asian gene & cell therapy company on its strategic overseas acquisition.
Advised a listed Asian pharmaceutical company on its strategic overseas acquisition.
Advised a European advanced cell therapy regenerative medicine company on its sale.